
Intrahepatic Arterial Delivery of Sorafenib Eluting Beads: A Pharmacokinetics Study
Author(s) -
Eerdunbageing,
Zhijun Wang
Publication year - 2020
Publication title -
journal of advances in medicine science
Language(s) - English
Resource type - Journals
eISSN - 2591-7617
pISSN - 2591-7609
DOI - 10.30564/jams.v3i2.1539
Subject(s) - sorafenib , lipiodol , pharmacokinetics , cmax , bottle , in vivo , chemistry , bead , chromatography , medicine , pharmacology , hepatocellular carcinoma , materials science , biology , microbiology and biotechnology , composite material
Objective: To determine the slow-release effect of Sorafenib carried beads and its impact on the normal liver of dogs. Materials and Methods: (1) To obtain the maximal drug-carrying of beads, different sizes of beads (300-500 μm and 500-700 μm) were tried. Five bottles of different sizes of beads were added into 75% solution of Sorafenid-alcohol with different concentrations: Bottle a,50mg/20ml; Bottle b, 100mg/20ml; Bottle c, 100 mg/40ml; Bottle d, 200mg/40m; Bottle e, 250mg/50ml. (2) In vivo study: 12 dogs were randomly divided into four groups [group A, Sorafenib carried bead (500-700μm); group B, only bead (300-500μm) ; group C, Lipiodol-sorafenib and four dogs in each group. Each group was treated with TAE with emulsion mentioned above. Sorafenib concentration in plasma and liver tissue was determined with HPLC respectively. Result: (1) In vitro research: Sorafenib can be dissolved into 75% alcohol and the best concentration for drug-carrying was 100mg/20ml. (2) In vivo study: ① Compared with group D, the Cmax and AUC in plasma in group A and B has a significant statistics difference(p<0.05). ② Sorafenib concentration in liver tissue could be determined in group A in the 3rd day and even after one week while it could not be determined in group D. Conclusion: Sorafenib can be carried in DC-Bead in a certain condition. Compared with emulsion with Sorafenib and lipiodol, DC-bead has a definite slow-release function and it is superior to lipiodol.